Inclusion Criteria:

- Patient or family able and willing to give informed consent.

- Subjects with metastatic cancer to the brain who have failed at least one
conventional therapy (surgery, stereotactic radiosurgery, and/or whole brain
radiotherapy).

- Three or fewer previously treated or untreated lesion(s) in the brain.

- Tumor size ≤ 3.0 cm in largest diameter.

- MR imaging is not contraindicated for the patient.

- Lesion(s) are clearly defined on pre-therapy contrast enhanced MRI scans as
determined by the treating surgeon.

- Able and willing to attend all study visits.

- Karnofsky Performance Scale score >70 for patients over the age of 15.

- Lansky Play Scale >70 for patients 15 years of age or younger.

Exclusion Criteria:

- Patients or family unwilling or unable to give written consent.

- Patients who cannot physically fit in, or are too heavy for, the MRI scanner.

- Patients with contra-indications to MRI imaging, such as, but not limited to,
pacemakers or defibrillators, non-compatible aneurysm clips, shrapnel, or other
internal ferromagnetic objects.

- Known sensitivity to gadolinium-DTPA.

- Based on Treatment Planning Imaging (MR and/or CT):

- Brain edema and/or mass effect that causes midline shift or shift in wall of
ventricle of more than 5 mm.

- Lesions localized in the brain stem.

- Lesions less than 5mm from primary branches of cerebral vessels, venous sinus,
hypophysis or cranial nerves.

- Evidence of recent (<2 weeks) hemorrhage.

- Presence of more than 3 brain tumors at the time of enrollment.

- Symptoms and signs of increased intracranial pressure.

- Medical issues which prohibit the patient from undergoing surgery (as determined by
the treating surgeon, anesthesiologist, IMPAC clinic, referring physician).

- Patients who are unable to receive corticosteroids.

- Positive pregnancy test for women of child-bearing age.